Aggregator

A short burst of immunotherapy before surgery is delivering surprisingly powerful results for a specific type of colorectal cancer. Patients in a UK-led trial who received just nine weeks of pembrolizumab prior to surgery have remained cancer-free nearly three years later—an outcome that challenges the standard approach of surgery followed by months of chemotherapy.

A major 10-year clinical trial is turning one of the world’s most common knee surgeries on its head. Researchers found that trimming a damaged meniscus—a procedure long believed to relieve pain—offers no real benefit over placebo surgery. Even more surprising, patients who had the operation actually fared worse over time, with more symptoms, poorer function, faster progression of osteoarthritis, and a greater likelihood of needing additional surgery.

Two high-profile tools have been shown to make up data and “p-hack” their results

A chaotic sleep schedule in your 40s might be quietly setting the stage for heart trouble later. Researchers tracking thousands of people for over a decade found that those with highly inconsistent bedtimes—especially when they slept less than eight hours—faced about double the risk of serious cardiovascular events like heart attacks or strokes. Interestingly, it wasn’t when people woke up that mattered most, but how erratic their bedtime was.

A revived technique could reveal planets near their stars and the inner workings of galaxies

Ganymede discovery could force rethink of how worlds power their magnetic fields

Scientists have developed a breakthrough injectable biomaterial that travels through the bloodstream to repair damaged tissue from within, reducing inflammation and jumpstarting healing. In animal studies, it successfully treated heart attack damage and even showed promise for conditions like traumatic brain injury and pulmonary hypertension. Unlike earlier approaches that required direct injection into the heart, this new therapy can be delivered intravenously, allowing it to spread evenly and act quickly.

GLP-1 weight-loss drugs like Ozempic and Wegovy are often celebrated as game-changing solutions—but new research reveals a surprising social twist. People who lose weight using these medications may actually face more judgment than those who lose weight through diet and exercise—or even those who don’t lose weight at all. The stigma seems rooted in a perception that these drugs are an “easy way out,” creating a double bind where individuals are judged both for their weight and for how they choose to manage it.

Questions about the culprit virus and its route of spread remain as health officials make plans for stranded passengers